Marinus Pharmaceuticals, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Immedica Pharma AB finalizes its acquisition of Marinus Pharmaceuticals, taking the company private after a successful tender offer and subsequent merger.
Immedica Pharma AB will acquire Marinus Pharmaceuticals, Inc. for $0.55 per share in a cash tender offer, valuing the company at approximately $151 million.
Marinus Pharmaceuticals has terminated its collaboration, manufacturing, and supply agreements with Orion Corporation, effective December 23, 2024, as part of a strategic review.
Marinus Pharmaceuticals has approved a retention plan for senior management and amended its change in control severance plan as it explores strategic alternatives.
Marinus Pharmaceuticals has received notices from Nasdaq for failing to meet the minimum bid price and market value requirements for continued listing.
Marinus Pharmaceuticals reports the immediate resignation of three board members, leading to a reduction in the board's authorized size from nine to six.
Marinus Pharmaceuticals announced its Q3 2024 financial results, highlighted by a 56% increase in ZTALMY revenue compared to Q3 2023, while also initiating a strategic review due to recent clinical trial disappointments.
Marinus Pharmaceuticals' Phase 3 TrustTSC trial for oral ganaxolone in tuberous sclerosis complex did not meet its primary endpoint, leading to a strategic review and cost-cutting measures.
8-K: Marinus Pharmaceuticals Wins Patent Challenge as PTAB Denies Ovid Therapeutics' Review Petition
Marinus Pharmaceuticals successfully defended its patent for ganaxolone in treating status epilepticus as the Patent Trial and Appeal Board denied Ovid Therapeutics' petition for Inter Partes Review.
Marinus Pharmaceuticals is on track to report topline data for its TrustTSC trial in tuberous sclerosis complex (TSC) in the first half of Q4 2024, with a planned NDA filing in April 2025.
Marinus Pharmaceuticals announced a significant 87% increase in ZTALMY net product revenue for Q2 2024 compared to Q2 2023, alongside key clinical trial advancements.
Marinus Pharmaceuticals' Phase 3 RAISE trial for IV ganaxolone in refractory status epilepticus met one co-primary endpoint but failed on the other, leading the company to prioritize its ZTALMY franchise.
Marinus Pharmaceuticals has amended its credit and revenue interest financing agreements, removing a minimum liquidity covenant and reducing near-term debt payments, extending its cash runway into the second quarter of 2025.
Marinus Pharmaceuticals' stockholders approved the 2024 Equity Incentive Plan, authorizing 4 million new shares for issuance, plus shares from the 2014 plan.
Marinus Pharmaceuticals has completed enrollment in its Phase 3 TrustTSC trial for ganaxolone in Tuberous Sclerosis Complex and secured a new method of use patent.
Marinus Pharmaceuticals announced a 125% increase in ZTALMY net product revenue for Q1 2024 compared to Q1 2023, along with updates on clinical trials and cost reduction plans.
8-K: Marinus Pharmaceuticals Provides Update on RAISE Trial and Reports Preliminary Q1 2024 Financials
Marinus Pharmaceuticals announced the RAISE trial did not meet interim stopping criteria, completed enrollment, and reported preliminary Q1 2024 revenue between $7.4 and $7.6 million.
Marinus Pharmaceuticals is actively defending its patent for ganaxolone use in treating status epilepticus following a challenge by Ovid Therapeutics, while also pursuing a post-grant review of an Ovid patent.
8-K: Marinus Pharmaceuticals Reports Q4 and Full Year 2023 Results, Provides Clinical Pipeline Update
Marinus Pharmaceuticals announced its Q4 and full year 2023 financial results, highlighted by ZTALMY revenue growth and progress in clinical trials for ganaxolone.